Anavex Life Sciences Corp.
HealthcareNASDAQ:AVXL · NASDAQ Global Select
+$0.00 today
Vol 1.20M · Avg 1.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-48.9%
avg -79.3%
ROIC
-54.2%
avg -15.1%
ROA
-44.7%
avg -63.2%
Analysis
ROA is currently the strongest return metric at -44.7% versus its period average of -63.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher U. Missling | President, Chief Executive Officer, Secretary & Director | $876,085.00 | — | 60 | $125,000.00 | 0.13% |
Sandra Boenisch | Principal Financial Officer & Treasurer | $247,070.00 | — | 45 | $12,500.00 | 0.01% |
Clint Tomlinson | Vice President of Corporate | — | — | — | — | — |
Adebayo Laniyonu | Senior Vice President of Nonclinical Development | — | — | — | — | — |
Juan Carlos Lopez-Talavera | Senior Vice President & Head of Research and Development | — | — | — | — | — |
Terrie Kellmeyer | Interim Chief Executive Officer | — | — | — | $0.00 | <0.01% |
Wolfgang Liedtke | Senior VP & Global Head of Neurology | — | — | — | — | — |
Kun Jin | Vice President & Head of Biostatistics | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
Absci Corporation
NASDAQ:ABSI
$1.06B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Who manages AVXL?
Anavex Life Sciences Corp. (AVXL) lists 8 active executives. The top listed executive is Clint Tomlinson, Vice President of Corporate.
Are AVXL insiders buying or selling?
Recent insider activity shows net buying of $38.10M.
Explore More
Continue the stock analysis
Jump to another research area for this company.